Presentation is loading. Please wait.

Presentation is loading. Please wait.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Similar presentations


Presentation on theme: "Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute."— Presentation transcript:

1 Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia  Yi-Bin Chen, Erin Coughlin, Kevin F. Kennedy, Edwin P. Alyea, Philippe Armand, Eyal C. Attar, Karen K. Ballen, Corey Cutler, Bimalangshu R. Dey, John Koreth, Steven L. McAfee, Thomas R. Spitzer, Joseph H. Antin, Robert J. Soiffer, Vincent T. Ho  Biology of Blood and Marrow Transplantation  Volume 19, Issue 6, Pages (June 2013) DOI: /j.bbmt Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Acute and chronic GVHD. (A) Shows cumulative incidence of grades II to IV acute GVHD. (B) Shows cumulative incidence of chronic GVHD. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Cumulative incidence of disease relapse and nonrelapse mortality. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Progression-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Overall survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 Propensity Score. Effect of Bu2 (versus Bu1) on 2-year progression-free survival. Propensity adjusted model for all patients and subgroups classified by clinical risk and cytogenetic risk. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 Causes of nonrelapse mortality. (A) Shows causes of nonrelapse mortality for patients in Bu1. Cases under “Other” include 1 case of massive autoimmune hemolytic anemia and 1 case of intracranial hemorrhage. (B) Shows causes of nonrelapse mortality for patients in Bu2. Cases under “Other” include 1 case of multi organ failure, 1 ruptured abdominal aortic aneurysm, and 1 unknown etiology who was lost to follow-up. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute."

Similar presentations


Ads by Google